Predict your next investment

HEALTHCARE | Biotechnology
avax-tech.com

See what CB Insights has to offer

Founded Year

1990

Stage

Unattributed VC - IV | Alive

Total Raised

$39.27M

Last Raised

$3.05M | 18 yrs ago

About AVAX Technologies

AVAX Technologies is a Healthcare/Biotechnology company based in Philadelphia, Pennsylvania. AVAX Technologies' investors include Precept Capital Management, Essex Woodland Health Ventures, PKB Privatbank AG, Soros Fund Management, Pequot Capital Mangement, Bank Julius Baer and Perot Investments.

AVAX Technologies Headquarter Location

2000 Hamilton Street Suite 204

Philadelphia, Pennsylvania, 19130,

United States

215-241-9760

Latest AVAX Technologies News

University of Tokyo to Evaluate AVAX's Breast Cancer Vaccine

Mar 20, 2017

AVAX Technologies Inc. (Kansas City, MO) and the University of Tokyo have entered into a collaborative research agreement to evaluate the application of the AVAX's patented AC Vaccine technology for the treatment of breast cancer. As part of the agreement, AVAX will provide the university with access to its technology in order to manufacture the vaccine for a clinical trial in Japan. The trial will be supported in part by a grant from the Noguchi Medical Foundation. AVAX's AC Vaccine technology is made from a patient's own cancer cells by modifying the tumor cells with a molecule called a hapten. This process, known as haptenization, alters the tumor cells and makes them appear foreign to the patient's immune system. When the hapten-modified cells are reinjected into patients, they stimulate the immune system to recognize the cancer cells and destroy them. AVAX is conducting a pivotal registration trial of the vaccine in malignant melanoma (M-Vax) and a Phase I/II trial in ovarian cancer (O-Vax) in the U.S. The collaborative research agreement with the University of Tokyo extends clinical development of the technology to a third indication. AVAX Technologies Inc. specializes in the development and commercialization of novel biotechnologies, immunotherapies, and pharmaceuticals for cancer and other life-threatening diseases. For more information: Jeffrey M. Jonas, President and CEO, AVAX Technologies Inc., 4520 Main St., Ste. 930, Kansas City, MO 64111. Tel: 816-960-1333. Fax: 816-960-1334. Like what you are reading? Sign up for our free newsletter SIGN ME UP By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AVAX Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AVAX Technologies is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

AVAX Technologies Patents

AVAX Technologies has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/26/2013

Vaccines, Clusters of differentiation, Immunology, Experimental cancer drugs, Oncology

Application

Application Date

7/26/2013

Grant Date

Title

Related Topics

Vaccines, Clusters of differentiation, Immunology, Experimental cancer drugs, Oncology

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.